Patents by Inventor Ryan Montier

Ryan Montier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
    Patent number: 11572541
    Abstract: Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 7, 2023
    Assignees: Providence Health & Services—Oregon, AgonOx, Inc.
    Inventors: Andrew D. Weinberg, Ryan Montier, Thomas Duhen, Rebekka Duhen